Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH
  • Correction 22 April 2024

The antibody–drug conjugate landscape

  1. Patrick Flynn

    1. Boston Consulting Group, Chicago, IL, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Smruthi Suryaprakash

    1. Boston Consulting Group, Mumbai, India.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Dan Grossman

    1. Boston Consulting Group, Chicago, IL, USA; Present address: Psychedelic Science Funders Collaborative, Chicago, IL, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Val Panier

    1. Boston Consulting Group, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. John Wu

    1. Boston Consulting Group, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Antibody–drug conjugates (ADCs) have become a key therapeutic modality in oncology, spurred by superior clinical profiles compared to standard-of-care chemotherapy across multiple indications. Consequently, revenue from approved ADCs and those in phase III development is forecasted to reach $26 billion in 2028 (Supplementary Fig. 1).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41573-024-00064-w

Updates & Corrections

  • Correction 22 April 2024: Figure 1 has been updated to show the correct number of approved products for the top 10 targets and include the label for the pH-sensitive Ab carrier category.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's healthcare practice.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links